Background: p16-positive oropharyngeal squamous cell carcinoma (OPSCC) usually responds to treatment and is known as a disease with a favorable prognosis. In this retrospective study, we sought the optimal initial treatment for Stage Ⅲ p16-positive OPSCC.
Methods: We compared the treatment outcomes and patient background factors of 23 patients who underwent curative treatment at our department between March 2006 and March 2020 by univariate analysis.
Results: Initial treatment included 13 patients treated with chemoradiotherapy (CRT), 3 patients treated with induction chemotherapy (ICT), 2 patients treated with surgery, and 5 patients treated with other methods. The 5-year overall survival (OS) rate was 78% and the 5-year recurrence-free survival (RFS) rate was 69%. The 5-year OS by initial treatment (CRT/ICT/surgery/other) was 77%/67%/50%/100% and the 5-year RFS was 69%/67%/0%/100%. Seven patients under the age of 60 years survived without recurrence. Among those who underwent CRT or ICT, all patients who smoked less than 20 pack-years survived.
Conclusion: In this study, the results of CRT and ICT for Stage Ⅲ p16-positive OPSCC were relatively favorable (70%), but the prognosis was poor for patients who smoked more than 20 pack-years and were over 60 years old.
View full abstract